Swedish Orphan Biovitrum
267,2 SEK -1,84%3 investorer følger denne virksomhed
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Omsætning
22,12 mia.
EBIT %
18,38 %
P/E
35,77
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SOBI
Daglig lav / høj pris
267,2 / 274
SEK
Markedsværdi
94,68 mia. SEK
Aktieomsætning
52,87 mio. SEK
Volumen
197 t
Finanskalender
Delårsrapport
25.04.2024
Generalforsamling
14.05.2024
Delårsrapport
16.07.2024
Delårsrapport
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Investor | 34,7 % | 34,7 % |
Morgan Stanley Smith Barney | 9,9 % | 9,9 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Swedish Orphan Biovitrum AB: Sobi to present new data at EAHAD 2024
Swedish Orphan Biovitrum AB: Sobi's Chairman of the Board resigns due to health reasons
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools